Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

MSC-EVs Prevent Abdominal Aortic Aneurysm Formation by Inhibiting Perivascular Adipose Tissue-Induced NET Release.

Sun X., Zhao C., Tu K., Guan X., Lv L., Xue G.

Animal Study on Systemic / IV, published in Stem Cells Int (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cells Int (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
42281962
DOI
10.1155/sci/8147359

Abstract (original English)

Perivascular adipose tissue (PVAT) envelops arteries and exerts paracrine effects, thereby modulating cardiovascular pathologies. Nevertheless, its precise role in abdominal aortic aneurysm (AAAs) pathogenesis remains elusive. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have been implicated in the regulation of neutrophil extracellular traps (NETs) formation. This investigation delineates PVAT's involvement in AAA, particularly in NETs regulation, and evaluates the modulatory impact of MSC-EVs on these processes. A comprehensive analysis of CT imaging and clinical datasets from AAA patients was undertaken. Subsequent RNA sequencing and transcriptomic profiling of PVAT from AAA animal models and controls were conducted. Both in vivo and in vitro assays were employed to determine whether PVAT-derived proteins influence NETs release within the abdominal aorta and contribute to AAA development. Additionally, MSC-EVs were administered via intravenous or intraperitoneal routes to assess their effects on PVAT accumulation and NETs formation. A significant correlation was established between PVAT characteristics and clinical outcomes in AAA patients. Experimental findings reveal that PVAT-derived serum amyloid A (SAA) promotes PVAT accumulation and induces NETs release within the abdominal aorta during AAA formation. Intraperitoneal MSC-EVs administration mitigates A

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research